Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 218-223

  Tani, Yoshihiro ^a   Ogata, Atsuto ^a   Koyama, Makoto ^a   Inoue, Teruyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Dyskinesia; Motor fluctuation; Parkinson's disease; Piclozotan; Serotonin 1A receptor agonist; SUN N4057

Indexed keywords

DOPAMINE; LEVODOPA; PICLOZOTAN; SEROTONIN 1 AGONIST; SUN N 4057; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DYSKINESIA; FORELIMB; HYPERKINESIA; MALE; MICRODIALYSIS; MOTOR DYSFUNCTION; NONHUMAN; OSMOTIC PUMP; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENSERAZIDE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG PARTIAL AGONISM; DYSKINESIA, DRUG-INDUCED; HYPERKINESIS; LEVODOPA; MALE; MICRODIALYSIS; MOTOR ACTIVITY; OXAZEPINES; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 78049251350     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.013     Document Type: Article

References (32)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferrard L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
3. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res. 1994, 667:295-299.
4. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rats: a double-labeling immunofluorescence study. Neurosci. Lett. 1995, 195:195-198.
5. Ba M., Kong M., Ma G., Yang H., Lu G. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res. 2007, 1127:177-184.
6. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., Chase T.N. Effects of serotonin 5-HT1A agonists in advanced Parkinson's disease. Mov. Disord. 2005, 20:932-936.
7. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
8. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17:73-82.
9. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
10. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT1A agonist buspirone reduces the expression and development of dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
11. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch. Neurol. 1999, 56:529-535.
12. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol. 2008, 7:927-938.
13. Goetz C.G., Damier P., Hicking C., Laska E., Müller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 2007, 22:179-186.
14. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with/increased motor disability. J. Pharmacol. Exp. Ther. 2006, 319:1225-1234.
15. Kamei K., Maeda N., Ogino R., Koyama M., Nakajima M., Tatsuoka T., Ohno T., Inoue T. New 5-HT1A receptor agonists possessing 1, 4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 2001, 11:595-598.
16. Kamei K., Maeda N., Katsuragi-Ogino R., Koyama M., Nakajima M., Tatsuoka T., Ohno T., Inoue T. New piperidinyl- and 1, 2, 3, 6-tetrahydropyridinyl- pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 2005, 15:2990-2993.
17. Kamei K., Maeda N., Nomura K., Shibata M., Katsuragi-Ogino R., Koyama M., Nakajima M., Inoue T., Ohno T., Tatsuoka T. Synthesis, SAR studies, and evaluation of 1, 4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect; Discovery of Piclozotan. Bioorg. Med. Chem. 2006, 14:1978-1992.
18. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. Brain Nerve 2002, 54:133-137.
19. Kleedorfer B., Lees A.J., Stern G.M. Buspirone in the treatment of levodopa induced dyskinesias. J. Neurol. Neurosurg. Psychiatry 1991, 54:376-377.
20. Matsubara K., Shimizu K., Suno M., Ogawa K., Awaya T., Yamada T., Noda T., Satomi M., Ohtaki K., Chiba K., Tasaki Y., Shiono H. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 2006, 1112:126-133.
21. Montastruc J.L., Rascol O., Senard J.M., Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five years follow up. J. Neurol. Neurosurg. Psychiatry 1994, 57:1034-1038.
22. Nicholson S.L., Brotchie J.M. 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 2002, 9(Suppl 3):1-6.
23. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000, 55:S13-S20.
24. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study). Clin. Neuropharmacol. 2004, 27:58-62.
25. Ouchchane L., Perrette S., Saikali N., Aublet-Cuvelier B., Durif F. Is levodopa-induced dyskinesias risk decreased in parkinsonian patients initially treated with dopamine agonist? A longitudinal study among 425 patients. Mov. Disord. 2004, 19(Suppl 9):S216-S217.
26. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
27. Sage J.I., Hauser R.A., Cordon M.E., Gonzalez M.A., Tani Y., Koyama M., Apfel S.C., Reed R.F., Okamoto M., Gertner J.M. Pilot study of the efficacy and safety of piclozotan in Parkinson's disease (PD) patients with l-dopa induced motor complication. Mov. Disord. 2009, 24(Suppl.1):S277.
28. Steece-Collier K., Collier T.J., Danielson P.D., Kurlan R., Yurek D.M., Sladek J.R. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats. Mov. Disord. 2003, 18:1442-1454.
29. Swanson L.W. Brain Maps: Structure of the Rat Brain 1992, Elsevier.
30. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
31. Tani Y., Saito K., Imoto M., Ohno T. Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain-an in vivo microdialysis study. Eur. J. Pharmacol. 1998, 351:181-188.
32. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., Arai R. Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res. 2007, 59:1-7.